Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 1.00 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirofiban SCHEMBL17721319 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL618214 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL155170 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL28858023 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41327 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL140366 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41325 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL7388934 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41326 | 0.97 | ITGB3 (0.95) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13873863 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18519 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4705465-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4684213-A1 | METHODS FOR ASSESSING PLATELET FUNCTION | University of Reading (GB) | 2026-01-28 | — | — | EP | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| WO-2000053605-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | claimed |
| EP-1034256-A1 | ANTICOAGULANT TEST | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| US-6103705-A | Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-08-15 | — | — | US | claimed |
| US-5972967-A | INTRAVENOUS ADMINISTERING 2-(BUTYLSULFONYLAMINO)-3-(4-(4-(PIPERIDIN-4-YL)BUTOXYPHENYL)PR OPIONIC ACID | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | claimed |
| EP-0946185-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1999038827-A1 | PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST | MERCK & CO., INC. (US) | 1999-08-05 | — | — | WO | claimed |
| WO-1999027962-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | WIEMANN GUNDULA (DE) | 1999-06-10 | — | — | WO | claimed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998023279-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-04 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |